ReviewThe role of peroxisome proliferator-activated receptor α in transcriptional regulation of novel organic cation transporters
Introduction
Peroxisome proliferator-activated receptor α (PPARα) is a ligand-activated transcription factor that acts as an important regulator of lipid metabolism and energy homeostasis (Desvergne and Wahli, 1999). PPARα is abundantly expressed in tissues with high rates of fatty acid oxidation such as liver, heart muscle, skeletal muscle, and kidney (Mandard et al., 2004). Transcriptional regulation of genes by PPARα is mediated by binding of activated PPAR/retinoid X receptor heterodimers to specific DNA sequences, called peroxisome proliferator response elements (PPREs) present in and around the promoter of target genes (Qi et al., 2000, Schoonjans et al., 1997, Tan et al., 2005), thereby stimulating the expression of those genes. Proteins encoded by these genes are involved in all aspects of fatty acid catabolism including cellular fatty acid uptake, intracellular fatty acid transport, fatty acid transport through the mitochondrial membrane, mitochondrial and peroxisomal fatty acid oxidation, ketogenesis as well as gluconeogenesis (Kersten et al., 1999, Mandard et al., 2004).
PPARα can be activated by both endogenous and synthetic ligands. Endogenous ligands of PPARα are fatty acids and their derivatives (eicosanoids). Endogenous ligand-activation of PPARα is observed during fasting (Kersten et al., 1999, Leone et al., 1999), since free nonesterified fatty acids are released from adipose tissue and taken up into tissues at increased levels during this state. Consequently, in the liver, where PPARα is most abundant, β-oxidation, ketogenesis as well as gluconeogenesis are dramatically elevated as a consequence of the increased expression of PPARα target genes (Kersten et al., 1999, Mandard et al., 2004). The crucial role of PPARα during fasting is evidenced by the fact that PPARα-null mice cannot sustain long-term fasting (Leone et al., 1999), because these animals are unable to adapt to food deprivation by stimulating β-oxidation, ketogenesis, and gluconeogenesis. Thus, PPARα-null mice develop hepatic steatosis and become hypoketonemic and hypoglycemic in response to a fasting challenge, despite marked elevations in circulating free fatty acids (Finck and Kelly, 2002, Hashimoto et al., 2000, Lee and Gonzales, 1996, Leone et al., 1999). In addition to endogenous ligands, PPARα is also activated by a heterogenous group of synthetic compounds including the fibrate class of lipid lowering drugs (clofibrate, fenofibrate, bezafibrate, and gemfibrozil) (Forman et al., 1997, Krey et al., 1997).
Regarding the expression of PPARα in tissues and the effects of PPARα activation on transcription of its target genes, there are great differences between various species. In rodents, PPARα is highly expressed in tissues, and activation of PPARα not only induces many genes involved in various metabolic pathways but also causes severe peroxisome proliferation, hypertrophy, hyperplasia, and even hepatocarcinogenesis in the liver (Peters et al., 2005). In contrast to rodents, PPARα agonists like fibrates do not induce peroxisome proliferation in several other species such as guinea pigs, pigs, monkeys and humans. These species have a lower expression of PPARα in the liver and the response of many genes to PPARα activation is much weaker than in rodents (Holden and Tugwood, 1999). Due to the great differences in the response to PPARα activation with respect to hepatic proliferation, rodents are commonly designated as proliferating species while those which do not respond with hepatic peroxisome proliferation are often called non-proliferating species. According to differences in PPARα expression and the response of target genes, PPARα activation observed in rodents cannot be directly applied for non-proliferating species such as humans. In contrast, mRNA concentration of PPARα in the liver in pigs is similar to that in humans (Luci et al., 2007a), which is approximately ten-fold lower than in rats. This suggests that the pig is a useful model to study the biochemical effects of PPARα agonists. Moreover, the pig is generally considered as a suitable model object for humans because it has similar metabolic features and anatomic conditions (Schwartz et al., 1996, Sigel et al., 1994, Spurlock and Gabler, 2008).
Many years ago it has been shown that starvation or treatment of rats with clofibrate increases the hepatic concentration of carnitine (Brass and Hoppel, 1978, McGarry et al., 1975, Paul and Adibi, 1979, Paul et al., 1986), an essential metabolite that is required for the β-oxidation of long-chain fatty acids in the mitochondrial matrix (Brass, 2004, McGarry and Brown, 1997, Steiber et al., 2004). Carnitine is derived from both dietary sources and endogenous biosynthesis which occurs in humans in liver, kidney and brain exclusively (Rebouche and Seim, 1998, Vaz and Wanders, 2002). Tissues which are incapable of producing carnitine are highly dependent on active carnitine uptake from blood. Since both, fasting and clofibrate treatment lead to an activation of PPARα, the hypothesis has been raised that activation of this nuclear receptor either stimulates carnitine biosynthesis and/or uptake of carnitine from the blood into tissues (Luci et al., 2006). Recent studies have shown that activation of PPARα indeed stimulates carnitine synthesis and leads to an up-regulation of novel organic cation transporters (OCTN) which facilitate the transport of carnitine through cell membranes. An overview about studies dealing with the effects of PPARα activation on the expression of OCTN is presented in chapter 2 of this review.
OCTN belong to the solute carrier (SLC) 22A family (Lahjouji et al., 2001, Tein, 2003). Three OCTN have been identified so far, OCTN1, OCTN2 and OCTN3 (Tamai et al., 1997, Tamai et al., 1998, Tamai et al., 2000), localised in the plasma and the mitochondrial membrane, respectively, of cells. OCTN1 and OCTN2 are expressed in several tissues such as kidney, intestine, skeletal muscle, heart, liver and brain (Ohashi et al., 2001, Tamai et al., 2000, Wu et al., 1999). OCTN3 has been found only in the mouse and is expressed exclusively in testes, kidney and small intestine (Durán et al., 2005, Tamai et al., 2000). OCTN are polyspecific. All the three OCTN are able to transport carnitine, and the involvement in carnitine homeostasis might be their most important physiologic function. The fact that inborn or acquired defects of OCTN lead to primary or secondary systemic carnitine deficiency demonstrates their essential role in carnitine homeostasis (Lahjouji et al., 2004). Among the three OCTN, OCTN3 has the highest specificity for carnitine, OCTN1 has the lowest one (Tamai et al., 2000). OCTN operate on the intestinal absorption and renal reabsorption of carnitine and play a major role in tissue distribution by catalysing the uptake of carnitine into body cells. Due to its high binding affinity for carnitine and its wide expression, OCTN2 is the physiologically most important carnitine transporter, operating for the reabsorption of carnitine from the urine as well as playing a major role in tissue distribution. OCTN1 contributes less to carnitine transport than OCTN2 due to its low carnitine transport activity. In mice, OCTN3 may be important for carnitine uptake into testis, and may contribute to reabsorption of carnitine in kidney (Tamai et al., 2000). OCTN1 transports, besides carnitine, also the zwitterions ergothioneine and stachydrine and several monovalent organic cations such as tetraethylammonium, quinidine, pyrilamine and verapamil. OCTN2 is a Na+/carnitine cotransporter but can function alternatively as a polyspecific and Na+-independent organic cation uniporter. In the presence of Na+, OCTN2 transports also the zwitterionic β-lactam antibiotic cephaloridine, l-lysine and l-methionine. Tetraethylammonium, choline, verapamil and pyrilamine are cationic substrates which are Na+ independently transported by OCTN2 (Koepsell and Endou, 2004).
Section snippets
Evidence for the involvement of PPARα in the transcriptional regulation of OCTN in proliferating and non-proliferating species
Recently, it has been observed that treatment of rats, representing a proliferating species, with clofibrate leads to a strong increase of the hepatic mRNA content of OCTN2 (Luci et al., 2006). In accordance with these findings in rats, treatment of rat hepatoma cells also caused an up-regulation of OCTN2 (Luci et al., 2006). These findings suggested for the first time that PPARα activation leads to an up-regulation of OCTN2. Subsequent studies confirmed that treatment of rats with clofibrate
Physiological implications of PPARα-mediated up-regulation of OCTN
OCTN are mainly involved in whole-body homeostasis of carnitine. The abovementioned novel findings in rats, mice and pigs with respect to up-regulation of OCTN therefore clearly establish an essential role for PPARα in maintaining carnitine homeostasis in the fasted state. During fasting or energy restriction, activation of PPARα by nonesterified fatty acids released from adipose tissues causes an up-regulation of a comprehensive set of genes involved in fatty acid catabolism including
Conclusions and future perspectives
In addition to the well known function of PPARα as key regulator of fatty acid catabolism, the results from current studies in rats, mice and pigs now establish an essential role for PPARα in the transcriptional regulation of OCTN2 and OCTN3. A comparison of the studies in pigs with rodent studies shows that the up-regulation of OCTN in pigs is nearly as great as in rodents. Since a similarity exists in the gene response to PPARα agonists between pigs and humans, it is possible that
References (61)
- et al.
Carnitine metabolism in the fasting rat
J. Biol. Chem.
(1978) - et al.
Oxidized frying oil up-regulates hepatic acyl-CoA oxidase and cytochrome P450 4A1 genes in rats and activates PPARα
J. Nutr.
(2001) - et al.
Peroxisome proliferator-activated receptor α (PPARα) signaling in the gene regulatory control of energy metabolism in the normal and diseased heart
J. Mol. Cell. Cardiol.
(2002) - et al.
Mechanism of the inhibitory effect of zwitterionic drugs (levofloxacin and grepafloxacin) on carnitine transporter (OCTN2) in Caco-2 cells
Biochim. Biophys. Acta
(2006) - et al.
Carnitine transport by organic cation transporters and systemic carnitine deficiency
Mol. Gen. Metabol.
(2001) - et al.
PPARα agonists up-regulate organic cation transporters in rat liver cells
Biochem. Biophys. Res. Comm.
(2006) - et al.
Control of human muscle-type carnitine palmitoyltransferase I gene transcription by peroxisome proliferator-activated receptor
J. Biol. Chem.
(1998) - et al.
Dietary oxidized fat prevents ethanol-induced triacylglycerol accumulation and increases expression of PPARα target genes in rat liver
J. Nutr.
(2007) - et al.
Treatment with pharmacological peroxisome proliferator-activated receptor alpha agonist clofibrate causes upregulation of organic cation transporter 2 in liver and small intestine of rats
Pharmacol. Res.
(2007) - et al.
Clofibrate treatment up-regulates novel organic cation transporter (OCTN)-2 in tissues of pigs as a model of non-proliferating species
Eur. J. Pharmacol.
(2008)
Treatment with pharmacological peroxisome proliferator-activated receptor alpha agonist clofibrate increases intestinal carnitine absorption in rats
Pharmacol. Res.
Intimal hyperplasia producing thrombus organization in an experimental venous thrombosis model
J. Vasc. Surg.
The development of porcine models of obesity and the metabolic syndrome
J. Nutr.
Carnitine: a nutritional, biosynthetic, and functional perspective
Mol. Asp. Med.
Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1
FEBS Lett.
Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes
J. Steroid Biochem. Mol. Biol.
PPARα-activation results in enhanced carnitine biosynthesis and OCTN2-mediated hepatic carnitine accumulation
Biochim. Biophys. Acta
Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor α
J. Biol. Chem.
Pivalate-generating prodrugs and carnitine homeostasis in man
Pharmacol. Rev.
The up-regulation of hepatic acyl-CoA oxidase and cytochrome P450 4A1mRNA expression by dietary oxidized frying oil is comparable between male and female rats
Lipids
Peroxisome proliferation in liver of rats fed oxidized frying oil
J. Nutr. Sci. Vitaminol. (Tokyo)
Peroxisome proliferator-activated receptors: nuclear control of metabolism
Endocr. Rev.
OCTN3: a Na+-independent l-carnitine transporter in enterocytes basolateral membrane
J. Cell. Physiol.
Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ
Proc. Natl. Acad. Sci. U. S. A.
Uptake of cardiovascular drugs into the human heart: expression, regulation, and function of the carnitine transporter OCTN2 (SLC22A5)
Circulation
Defect in peroxisome proliferator-activated receptor α-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting
J. Biol. Chem.
Peroxisome proliferator-activated receptor α: role in rodent liver cancer and species differences
J. Mol. Endocrinol.
Organic cation/carnitine transporter OCTN2 (Slc22a5) is responsible for carnitine transport across apical membranes of small intestinal epithelial cells in mouse
Mol. Pharmacol.
Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting
J. Clin. Invest.
Dietary oxidised fat up regulates the expression of organic cation transporters in liver and small intestine and alters carnitine concentrations in liver, muscle and plasma of rats
Br. J. Nutr.
Cited by (26)
Clozapine-induced reduction of L-carnitine reabsorption via inhibition/down-regulation of renal carnitine/organic cation transporter 2 contributes to liver lipid metabolic disorder in mice
2019, Toxicology and Applied PharmacologyCitation Excerpt :Schurch et al. (2010) reported that reduced L-Car levels caused increases in renal OCTN2 expression and activity. Additionally, our results reveal that mRNA of peroxisome proliferators-activated receptor α (PPARα) was also down-regulated by clozapine (unpublished data), consistent with the report of Eder and Ringseis (2010) that PPARα contributes to OCTN2 regulation. Therefore, it is plausible to assume that clozapine-induced down regulation of OCTN2 may contribute to the reduction of L-Car levels in vivo.
The molecular and metabolic influence of long term agmatine consumption
2014, Journal of Biological ChemistryCitation Excerpt :The transcriptional activity of PPARα is enhanced by several coactivators, including PGC1α and -1β. These coactivators are required for the ability of PPARα to maximally increase gene transcription (12–15), thereby turning on downstream target genes such as those involved in carnitine (Car) biosynthesis and selected organic cation transporters (OCTN1 and OCTN2) (16–19). Activation of genes responsible for Car biosynthesis and transport is expected to have a significant impact on FAO and carbohydrate metabolism.
Impact of high altitude on the hepatic fatty acid oxidation and synthesis in rats
2014, Biochemical and Biophysical Research CommunicationsCitation Excerpt :Peroxisome proliferator-activated receptor alpha (PPARα) is a ligand-activated transcription factor and is highly expressed in the liver where it stimulates the β-oxidative degradation of FAs [23]. Activation of PPARα has been shown to affect the expression of 80–100 genes [24] and the proteins encoded by these genes are involved in all aspects of FA catabolism [23,25,26]. CPT-I is a direct downstream target for PPARα [19,27].
In-cell Western™ detection of organic cation transporters in bronchial epithelial cell layers cultured at an air-liquid interface on Transwell<sup>®</sup> inserts
2013, Journal of Pharmacological and Toxicological MethodsCitation Excerpt :The PPARα agonist fenofibrate enhanced OCTN1 levels while the PPARγ agonist rosiglitazone increased expression of OCTN1 and OCTN2, although the effect was more pronounced on the latest transporter (Fig. 4). Up-regulation of both OCTN sub-types upon activation of PPARα was demonstrated in various animal tissues (Eder & Ringseis, 2010). Conversely, regulation of OCTN2 in human and murine colonic epithelial cells was shown to be under the control of PPARγ independently of PPARα (D'Argenio et al., 2010), in line with our data in the Calu-3 cell line.
The SLC22 family with transporters of organic cations, anions and zwitterions
2013, Molecular Aspects of MedicineCitation Excerpt :In addition it is regulated by heat shock factor-1 (HSF1) (Koepsell et al., 2003) and by peroxisome proliferator-activated receptor γ (PPAR γ) (D’Argenio et al., 2010). Transcription of SLC22A5 is probably also regulated by peroxisome proliferator-activated receptor α which is increased during fasting or during treatment with lipid-lowering drugs of the fibrate class such as clofibrate (Eder and Ringseis, 2010; van Vlies et al., 2007). Human OCTN2 mediates the active step in absorption of l-carnitine in small intestine and in reabsorption of l-carnitine in the proximal tubule (Fig. 1).